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Abstract 
Background: Guidelines suggest statin use after acute myocardial infarction (AMI) 
should be close to universal in patients without safety concerns yet rates are much 
lower than recommended, decline with patient complexity, and display substantial 
geographic variation. Trial exclusions have resulted in little evidence to guide statin 
prescribing for complex patients. 
Objective:  Assess the benefits and risks associated with higher rates of statin use after 
AMI by baseline patient complexity. 
Research Design:  Sample includes Medicare fee-for-service patients with AMIs in 
2008-2009. Instrumental variable estimators using variation in local area prescribing 
patterns by statin-intensity as instruments were used to assess the association of higher 
statin prescribing rates by statin-intensity on 1-year survival, adverse events, and cost 
by patient complexity. 
Results: Providers appear to have individualized statin use across patients based on 
potential risks. Higher statin rates for non-complex AMI patients were associated with 
increased survival rates with little added adverse event risk.  Higher statin rates for 
complex AMI patients were associated with tradeoffs between higher survival rates and 
higher rates of adverse events. 
Conclusions: Higher rates of statin use for non-complex AMI patients are associated 
with outcome rate changes similar to existing evidence. For the complex patients in our 
study, who were least represented in existing trials, higher statin-use rates were 
associated with survival gains and higher adverse event risks not previously 
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documented.  Policy interventions promoting higher statin-use rates for complex 
patients may need to be re-evaluated taking careful consideration of these tradeoffs. 
 
Key Words: statins, effectiveness, survival, adverse events, costs, geographic variation, 
instrumental variables.  
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Introduction 
 Guidelines for statin use after acute myocardial infarction (AMI) have become 
more definitive over time as evidence has accumulated. Earlier guidelines focused on 
cholesterol reduction1-3 and provided qualifications for statin use such as absence of 
contra-indications3,4 and limited recommendations to like study patients.5  The latest 
European guideline however has no qualifications, stating, Statins should be given to 
all patients with acute myocardial infarction, irrespective of cholesterol concentration 
and given at high doses.6  The US 2013 ACC/AHA Cholesterol Guideline recommends 
high-intensity statin therapy following AMI in individuals up to age 75 years without heart 
failure or end-stage renal disease for whom there are no safety concerns. Lower-
intensity statins are recommended for patients >75 years or patients with safety 
concerns from high-intensity statins.7  Yet, studies show statin-use rates after AMI are 
much lower than guidelines recommend, decline with patient complexity, and display 
substantial geographic variation.8-11  In light of this, patient and provider interventions to 
encourage higher rates of statin use have been suggested.12 
 The source of this apparent underuse of statins does not appear to be insufficient 
evidence diffusion as an LDL-C of less than 100 mg/dl (defined as the goal of treatment 
in earlier US cholesterol guidelines13) was identified by 96% of US physicians as the 
treatment goal for high-risk patients.14 Alternatively, non-universal statin prescribing 
after AMI may reflect provider beliefs that statin benefits and risks are heterogeneous 
across patients and that the statin prescribing in practice is being individualized to 
patient circumstances. Randomized controlled trial (RCT) evidence supports the idea 
that absolute risk reductions from statins are heterogeneous across patients with 
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respect to factors such as diabetes or heart failure.15-18 In addition, although the rate of 
statin-related adverse events reported in RCTs were low, adverse events appear more 
often in practice and vary with statin intensity, patient age, gender, weight, health 
behaviors, comorbidities, and concomitant drug use.19-25   
 If providers are trying to limit statin prescribing to only those patients for whom 
they believe statin benefits outweigh risks, the relevant policy question then becomes 
whether statin-use rates after AMI represent an optimal sorting of statins across 
patients. Are existing rates right?26  If present statin-use rates are less than optimal, 
higher rates should yield survival gains sufficient to outweigh additional adverse effect 
risks and treatment costs.  Conversely, if statin-use rates after AMI are optimal, higher 
rates could result in higher healthcare costs and higher adverse effect rates with little 
added survival benefit.  Estimates of the benefits and risks of statins for AMI patients on 
the extensive margin27-29 are needed to address this question.  AMI patients on the 
extensive margin can be thought of as those who would be next to receive a statin if use 
rates increased, or those first not to receive a statin if rates were lowered. 
 The objective of this paper is to use the variation in statin practice styles for 
Medicare AMI patients across local areas found in earlier research11 to assess the 
benefits and risks of statins for patients on the extensive margin.  We use instrumental 
variable (IV) estimation methods to assess the effects of higher use rates of both lower-
intensity and high-intensity statins after AMI on survival rates, adverse event rates and 
healthcare costs. IV estimators yield estimates that are properly generalized to the 
subset of patients whose treatment choices were influenced by the instrument used in 
the study.30,31 Here we use instruments derived from the variation in statin practice 
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styles across local areas so that our estimates can be interpreted tangibly as what might 
be expected from interventions targeted at changing statin-use rates. Separate IV 
analyses are performed for complex patient subgroups because statin rates have been 
observed to vary with complexity. 
Methods 
Data and Study Cohort  
 Medicare claims files and enrollment information for all Medicare 
beneficiaries with an AMI in 2008 and 2009 were obtained based on the Chronic 
Condition Data Warehouse (www.ccwdata.org) definition of AMI (an inpatient 
claim with the primary diagnosis code 410.x1).  The study cohort contained all 
AMI Medicare patients with sufficient fee-for-service coverage to enable proper 
measurement of study variables.  The online appendix contains a full description 
of the exclusion criteria used.   The final corhort contained 124,813 patients.  In 
addition, because statin use after AMI was found to vary substantially with patient 
complexity, we stratified the cohort based on prior heart failure (N = 66,644), prior 
chronic kidney disease (N = 43,690), prior diabetes (N = 54,125), and patients with 
none of these three conditions prior to AMI admission (N = 31,170). 
Treatment Variables 
 Two binary statin treatment variables (lower-intensity and high-intensity) 
were specified for each patient to represent statin availability for use in the month 
after AMI discharge. High-intensity statins were defined as those that can lower 
LDL-C by 50% or more: atorvastatin 40,80mg; and rosuvastatin 20,40mg.  Lower-
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intensity statins were defined as those that lower LDL-C less than 50%: 
atorvastatin 10, 20mg; fluvastatin 20,40,80mg; lovastatin 10,20,40,80mg; 
rosuvastatin 5,10mg; pravastatin 10,20,40,80mg; and simvastatin 5, 
10,20,40,80mg.32  The online appendix provides the approach used to measure 
these binary variables using Medicare Part D event data.  
Outcome Variables 
 This study focused on four separate outcomes: 1-year survival; 1-year 
cardiovascular-event-free survival; 1-year occurrence of any adverse event found 
to be associated with statins in previous population studies25,33 (muscle-related 
inpatient and outpatient events; inpatient acute renal events, or inpatient acute 
hepatic events); and 1-year total healthcare cost from the perspective of the 
Medicare program.  Secondarily,  the 1-year occurrence of each distinct adverse 
event were analyzed.  The online appendix describes the approaches used to 
measure study outcomes and the ICD-9 codes and Medicare claims files used.    
Covariates 
 A list of the covariates specified in all estimation equations can be found in 
the online appendix.  Full definitions of these variables can be also found in a 
previous publication.11 
 
 
Instrumental Variable Strategy 
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 A linear two-stage least squares (2SLS) instrumental variable estimator with 
robust standard errors  was used to estimate the absolute effect of statins on each 
study outcome.  STATA software was used. Linear 2SLS yields consistent estimates of 
absolute treatment effects on outcomes for the group of patients whose treatment 
choices were influenced by the instrument specified regardless of underlying error 
distributions.  Further justification for this estimator can be found in the online appendixl. 
 The instruments used in this study were measures of local area statin practice 
styles for the AMI patients living around the residence ZIP codes of the patients in our 
sample.  We postulated that patients did not choose their residence in a manner related 
to unmeasured confounders for a future acute condition and that patients with an acute 
condition living in a local area with physicians having stronger preferences for a 
particular treatment are more apt to receive that treatment.  A full description of the local 
area practice style measurement approach used here is documented elsewhere.11  
Briefly, local areas were constructed for each patient ZIP code by consecutively adding 
AMI patients from the next closest ZIP codes based on driving times until at least 150 
patients were found.34 Robustness checks for alternative local area sizes were 
performed. For the patients in the local area around each ZIP code, area treatment 
ratios (ATRs) for no statin, lower-intensity statins and high-intensity statins were 
calculated as the ratio of the number of patients in the local area who received each 
respective statin intensity over the sum of the predicted probabilities across these 
patients of receiving that statin intensity. This approach to measure local area practice 
styles was found to explain a larger portion of treatment variation than other local area 
definitions and effectively balance measured covariates.34-36 
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Results 
 Table 1 provides average characteristics for our sample when patients are 
grouped by (1) post-AMI statin intensity and (2) the quintiles of the local area treatment 
ratio (ATR) for no statins. Patients using either a high or lower-intensity statin after 
AMI relative to patients without a statin were more likely younger, male, and living in a 
ZIP code that was metropolitan with a higher than average income and a higher than 
average life expectancy. Statin users also had fewer comorbidities as measured by the 
Charlson Score,37 had fewer prior conditions related to adverse events, were more likely 
to have used a statin previous to their AMI and more likely to have been initially 
prescribed other drugs.  Statin users had characteristics suggestive of more serious 
AMIs (more likely arterial wall, ST-elevation, and received cardiac catheterization) than 
non-users.  Statin users had higher unadjusted 1-year survival and cardiovascular-
event-free survival rates, lower 1-year acute renal and 1-year muscle-related event 
rates, and lower 1-year Medicare costs than non-users.  In addition, lower-intensity 
statin users had lower unadjusted 1-year hepatic event rates than non-users. 
 Comparisons across ATR quintiles provide some evidence as to whether our 
instruments provide a natural experiment in statin use.  In the first quintile 32.4% of 
patients had no statin available for use within 30 days of AMI discharge (67.6% had a 
stain available) compared to 43.6% of patients in the fifth quintile (56.4% had a stain 
available). While trends in several measured covariates across quintiles reached 
statistical significance, for the most part these differences were modest compared to 
when patients were grouped by statin use. Exceptions were mainly for demographic and 
socioeconomic characteristics.  Local areas with higher statin use (e.g. quintile 1) had 
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higher percentages of African Americans, patients who lived in a metropolitan area, and 
patients who lived in a ZIP code with a higher than average income than the other 
quintiles. No trends in unadjusted survival or Medicare cost were observed across 
quintiles. Unadjusted adverse event rates fell as statin-use rates fell moving from 
quintiles 1 to 5. 
 Table 2 contains average unadjusted 1-year outcomes for the full sample and by 
patient complexity. The adverse event rates for our population were much greater than 
what was reported for younger and less complex patients using statins.24 Survival and 
cardiovascular-event-free survival rates were lower in the complex patient subsets 
compared to the non-complex subset while Medicare costs and adverse event rates 
were higher in these subsets. 
 Table 3 summarizes our IV results for the full sample and subsets based on 
complex conditions. Alternative representations of Table 3 based on local areas 
using 100-patient and 200-patient thresholds around patient residence ZIP codes 
are available in the online appendix.  For each cohort, each row of Table 3 provides 
estimates by statin intensity.  Column 1 shows the percentage of patients using statins 
by intensity level and the inter-quintile range of these percentages across local area 
practice style quintiles. Estimates of the absolute effect of statin use on each outcome 
should be interpreted in terms of statin rate changes only within these ranges. Column 2 
contains the F-statistics testing whether the instruments had statistically significant 
impacts on lower-intensity and high-intensity statin use.38 The instruments had 
statistically significant impacts on both lower and high-intensity statin use for the full 
sample and within each complexity subset. Columns 3-9 contain the absolute effect 
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estimates of statin use by intensity on each study outcome relative to no statin.  For 
example, (.081) is the absolute effect estimate of lower-intensity statin use on 1-year 
survival for the marginal patients within the full sample relative to no statin.  This result 
can also be interpreted as follows: a one percentage point increase in the use of lower-
intensity statins within the range of 43% to 57% (e.g. increasing the lower-intensity 
percentage from 50 to 51) was associated with an .081 percentage point increase in 1-
year survival (e.g. 85.4 to 85.481) relative to no statin. The same one percentage point 
increase in lower-intensity statin use within this range led to an average decrease in 
Medicare costs for marginal patients of $2,370.  Across the full sample, higher statin-
use rates were associated with higher 1-year survival and cardiovascular-event-free 
survival rates (columns 3-4) with high-intensity statins showing greater additional 
survival benefit from higher use rates than lower-intensity statins.  Higher statin-use 
rates in the full sample were also associated with higher adverse event rates (columns 
5-8) with high-intensity statin-use rates being positively associated with higher rates of 
all three adverse advents.  Column 9 shows that average Medicare costs per marginal 
patient were reduced with greater statin-use rates but this association was only 
statistically significant for lower-intensity statins. 
 The statin treatment effect estimates stemming from rate differences across local 
areas varied with patient complexity.  AMI patients with no prior heart failure, no chronic 
kidney disease, and no diabetes had the highest use rates of both lower- and high-
intensity statins.  For this subset higher rates of high-intensity statin use were 
associated with survival gains and the absolute effect of this association was about half 
of what was found for the full sample.  No statistically significant associations with other 
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study outcomes were found for this patient subset.  Statin-use rates were lower for 
complex patients as compared to non-complex patients.  Complex patients had larger 
increases in 1-year survival and 1-year cardiovascular-event-free survival rates 
associated higher statin-use rates than non-complex patients. Conversely, higher statin-
use rates for complex patients were associated with higher adverse event rates than for 
non-complex patients.  Statin-use rates regardless of intensity were positively 
associated with acute hepatic events in each complex patient subset. Use rates of high-
intensity statins were positively associated with acute renal event rates in each complex 
patient subset. Higher statin-use rates did not have statistically significant associations 
with muscle-related adverse effects in any patient subset, but the estimates for these 
conditions were generally higher for complex patients than non-complex patients.  In 
addition, higher statin-use rates among complex patients were associated with larger 
reductions in 1-year Medicare costs than among non-complex patients. For patients 
with prior heart failure Medicare cost reductions of over $4,000 were found associated 
with greater statin-use rates for either statin intensity level.  
Discussion 
 Our results provide strong evidence that providers were attempting to 
individualize statin prescribing to patients after AMI. Statin users after AMI were less 
complex, had higher rates of prior statin use, and lower rates of prior hepatic, renal and 
muscle-related events as compared to the patients without a statin after AMI.  In 
addition, statin users had lower unadjusted 1-year post-AMI rates of acute renal events 
and muscle-related events than non-users.  Lower-intensity statin users also had lower 
post-AMI 1-year rates of acute hepatic events than non-users.  Because statins are not 
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considered protective with regard to these conditions, these unadjusted outcome 
comparisons suggest that providers purposely restricted statins from patients who were 
at higher risk of these adverse events.  
 Table 4 summarizes our results with regard to changes in statin-use rates after 
AMI.  For the non-complex patients in our study high-intensity statin-use rates were 
positively associated with 1-year survival with no additional adverse event risk.  These 
estimates are consistent with the 2013 ACC/AHA cholesterol guidelines in that patients 
should be on a high-intensity statin if safety concerns are not present.7  These 
guidelines were based on randomized controlled trials (RCTS) and meta-analyses of 
RCTs that showed survival gains and cardiovascular event risk reductions from statins 
with few reported adverse events.39,40 The non-complex patients in our sample were 
most closely aligned to the populations in these studies.  
 In contrast, outcome tradeoffs were associated with higher rates of statin use for 
the complex patients in our study.  From initially lower statin-use rates as compared to 
non-complex patients, higher statin-use rates for complex patients were associated with 
larger survival and cardiovascular-event-free survival rate increases than what was 
observed for non-complex patients.  These statin benefits were tempered by larger 
positive associations between statin-use rates and adverse event rates than what was 
observed for non-complex patients. Across the three complex patient subgroups, a one 
percentage point increase in statin-use rates was associated with between a .095 - .176 
increase in the proportion of patients with acute hepatic events over the next year, 
depending on statin intensity.  Likewise, a one percentage point increase in high-
intensity statin-use rates was associated with a .138 - .178 increase in the proportion of 
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patients with acute renal events over the next year.  While no estimate for muscle-
related adverse events was statistically significant within any complex patient subset, a 
positive association between high-intensity statin availability and muscle-related events 
over the entire sample appears to emanate from the associations seen within the 
complex patient subsets. The 2013 ACC/AHA cholesterol guidelines are clear that 
safety concerns should be considered in the statin prescribing decision.  The practice 
patterns we observed for complex patients may reflect provider attempts to incorporate 
safety concerns into practice in light of the limited RCT evidence available for complex 
patients. Indeed, the patients represented in the statin RCTs had far fewer complexities 
than the patients in our Medicare sample. Moreover, even the few statin RCTs that 
included more complex patients still had exclusions based on liver function, renal 
impairments, and muscular problems.41,42  Our study provides important new evidence 
of the stain side effect risks for older complex patients. 
 It is important to understand that our estimates should be generalized only to 
patients within each complex subset whose statin use would have changed had they 
resided in a local area with different statin prescribing preferences. The inter-quartile 
ranges in statin-use rates in Table 3 are the ranges within which our results should be 
interpreted.  Extrapolating our estimates outside these ranges is problematic if statin 
recommendations were individualized across patients based expected benefits and 
risks and our evidence suggests that providers were attempting to individualize statin 
use across patients. Consequently, our estimates only inform the discussion of whether 
existing statin-use rates should change within a window around the rates observed in 
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2008-2009 and not a discussion of whether statins should or should not be used 
generally within each patient subset defined by complexity.   
It should also be emphasized that validity of our estimates is based on the 
assumption that local area statin practice styles are not associated with unmeasured 
factors related to study outcomes.  This assumption is supported by previous research 
showing local area statin practice styles varying substantially across and within states11 
and that grouping patients by local area practice styles substantially reduced the 
imbalance in most measured clinical covariates as compared to grouping patients by 
actual statin use.  However, grouping patient by local area practice styles did 
exacerbate the imbalance in some demographic and socioeconomic variables relative 
to grouping patients by statin use.  While these factors were controlled for directly in our 
analysis, they could be symptomatic of other unmeasured differences across local 
areas that may confound our results.  For example, if statin use and unmeasured 
healthcare access were positively correlated it is possible that higher adverse event 
rates in areas with higher statin use are partially attributable to reporting bias.  Patients 
with greater access to healthcare may have greater opportunities to be diagnosed with 
adverse events. It is also possible that local area statin rates could be positively 
correlated with local area use of other types of aggressive care we have not 
measured. Table 1 shows a slight positive relationship between local area statin 
rates and rates of beta blockers and renin-angiotensin system antagonists after 
AMI.  While we controlled for the use of these drugs directly in our analysis, our 
results could be partially attributable to correlations with other unmeasured 
treatments. However, if unmeasured confounders were the predominant source of our 
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estimates we would expect to find higher adverse event rates associated with statin use 
across all complex patient subsets, rather than the specificity of the association for 
complex subsets only.   
 Statins are advocated for use after AMI with a proviso for safety concerns. 
Randomized controlled trial (RCT) evidence suggests that statin safety concerns are 
minimal which has led some to believe that statin prescribing post AMI should be close 
to universal and behavioral interventions be used to increase statin initiation.12  
However, statin RCTs have generally excluded the most complex patients.  Our study 
shows that most elderly AMI patients within Medicare are complex and would have 
been excluded from these trials and that providers have been individualizing statin use 
across Medicare patients based on perceived risks of adverse events that have not 
been observed in published evidence. Complex patients had lower statin-use rates than 
non-complex patients and the effects of higher statin-use rates on benefits and risks 
varied with patient complexity.  Higher rates of high-intensity statin use for non-complex 
AMI patients was associated higher survival rates with no additional adverse event risk 
which is consistent with RCT evidence.  In contrast, for complex patients who are 
unrepresented in the RCTs we showed that higher statin-use rates involves tradeoffs 
between survival benefits and adverse event risks.  Because of these tradeoffs, the 
right rate of statin use by complex patients remains unclear.  At a minimum our 
evidence suggests that promoting universal statin use among complex AMI patients 
over observed practice without consideration of the potential of safety issues may not 
be wise policy. 
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Table 2:  Unadjusted 1-Year Average Outcomes for Medicare AMI Patients 2008-2009 by 
Patient Complexity 
 
1-Year 
Outcome 
 
Full Sample 
(N=124,813) 
Non-
Complex 
Patientsa 
(N=31,170) 
 
Prior Heart 
Failure 
(N=66,644) 
Prior Chronic 
Kidney 
Disease 
(N=43,690) 
 
Prior 
Diabetes 
(N=54,125) 
Survival % 84.5 93.6 78.0 77.4 82.9 
Cardiovascular-
event free 
survival (%) 
75.9 87.1 68.4 67.3 72.4 
Medicare costs $10,802 $9,009 $12,046 $12,256 $11,715 
Acute renal 
events (%) 
15.6 4.1 22.1 30.1 20.6 
Acute hepatic 
events (%) 
3.8 2.7 4.4 4.9 4.3 
Muscle-related 
events (%) 
17.6 14.6 19.3 20.3 19.3 
a. Patients with no heart failure, chronic kidney disease, or diabetes 1-year prior to AMI 
admission. 
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 Table 4:  Summary of Effects Statin Rate Differences on Outcomes by Patient 
Complexity 
 
 
Complexity 
Lower-intensity statins High-intensity statins 
Rate 
rangea 
Estimated effects 
associated with higher 
rateb 
Rate 
rangea 
Estimated effects 
associated with higher 
rateb 
Benefit 
increasec 
Risk 
increased 
Benefit 
increasec 
Risk 
increased 
All Patients 43-57 yes yes 9-16 yes yes 
Non-Complex 47-64 no no 7-24 yes no 
Heart Failure 41-52 yes no 6-16 yes yes 
CKD 41-52 no yes 6-17 yes yes 
Diabetes 44-55 yes no 7-18 yes yes 
a. quintile range of statin utilization rates across local areas for respective complexity and age group. 
b. relative to no statin based on statin rates in 2008-2009 
c. yes if statistically significant increase in 1-year survival or 1-year cardiovascular event free survival 
rates is associated with a statin rate increase. 
d. yes if statistically significant increase in 1-year muscle-related adverse events, renal-related adverse 
events or hepatic-related adverse event rates is associated with a statin rate increase. 
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